文献速递产科母胎医学

妊娠期糖尿病及糖尿病治疗重大新进展:长效与超长效胰岛素的应用

Diabetes in pregnancy and major new advances in diabetes care using long-acting and ultralong-acting insulins.
PubMed 文献 · Am J Obstet Gynecol · 2025-08-29

妊娠期糖尿病占所有妊娠的1%至2%。胰岛素是妊娠期糖尿病治疗的一线药物和基石。本综述讨论德谷胰岛素在妊娠期应用的证据,以及每周一次超长效基础胰岛素在妊娠期的潜在获益与不足。

要点

  • 胰岛素类似物如甘精胰岛素和地特胰岛素是目前妊娠期最常用的基础胰岛素。
  • 德谷胰岛素在妊娠期与地特胰岛素同样有效,且每日一次注射不增加低血糖风险。
  • 每周一次基础胰岛素方案可减少注射频率,可能提高依从性并改善血糖控制。

核心结论

  • 德谷胰岛素在妊娠期与地特胰岛素同样有效,每日一次注射不增加低血糖风险。
  • 每周一次超长效基础胰岛素在妊娠期的潜在获益与不足有待进一步研究。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 妊娠期糖尿病占所有妊娠的1%至2%。
  • 德谷胰岛素在妊娠期与地特胰岛素同样有效。
  • 每周一次基础胰岛素方案可将每年基础胰岛素注射次数从至少365次减少至52次。

临床怎么用

  • 胰岛素是妊娠期糖尿病治疗的一线药物和基石;甘精胰岛素和地特胰岛素是目前妊娠期最常用的基础胰岛素。
  • 德谷胰岛素每日一次注射不增加低血糖风险,可简化胰岛素方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pregestational diabetes complicates 1% to 2% of all pregnancies. Achievement of euglycemia prevents adverse maternal, fetal, and neonatal outcomes. Insulin is the first line and the backbone of diabetes treatment in and out of pregnancy, but the delicate balance between stringent control and hypoglycemia, along with the complexity and interruption of multiple injections per day, continues to make glycemic control challenging. The ideal basal insulin has a flat pharmacodynamic profile with minimal variability and is relatively easy for patients and clinicians to use. Insulin analogs, such as insulins glargine and detemir, are the most common basal insulins used in pregnancy at this time, but insulin degludec, which has advantages like prolonged duration of action in the nonpregnant population, was recently shown to be equally as effective as detemir in pregnancy. The ease of a once-daily injection without an increased risk of hypoglycemia is attractive to patients and clinicians who wish to simplify insulin regimens. Furthermore, there are current clinical trials evaluating once-weekly basal insulin regimens in the general population. This would decrease basal injections from a minimum of 365 per year to 52 per year, potentially increasing adherence and improving glycemic control. This review will discuss the evidence for insulin degludec in pregnancy as well as discuss the potential benefits and drawbacks of once-weekly ultralong-acting basal insulins in pregnancy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Drummond RF, Seif KE, Higgs AJ, et al. Diabetes in pregnancy and major new advances in diabetes care using long-acting and ultralong-acting insulins. Am J Obstet Gynecol. 2025. PMID: 40886785. doi:10.1016/j.ajog.2025.08.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。